REPRO-MED Systems (KRMD)
NASDAQ:KRMD
Want to see KRMD full AI Analyst Report?
KRMD Stock Chart & Stats
$4.33
<$0.01(0.25%)
At close: 4:00 PM EST
$4.33
<$0.01(0.25%)
Day’s Range― - ―
52-Week Range$2.91 - $6.61
Previous CloseN/A
Volume31.78K
Average Volume (3M)198.68K
Market Cap
$183.73M
Enterprise Value$181.09M
Total Cash (Recent Filing)$8.77M
Total Debt (Recent Filing)$3.37M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Aug 12, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding45,933,000
10 Day Avg. Volume166,933
30 Day Avg. Volume198,682
Financial Highlights & Ratios
PEG Ratio1.81
Price to Book (P/B)15.74
Price to Sales (P/S)6.52
P/FCF Ratio-570.81
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue4.19
Enterprise Value/Gross Profit6.81
Enterprise Value/Ebitda-123.51
Forecast
1Y Price Target
$6.33Price Target Upside46.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$48.69M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue From ConsumablesA large installed base (~60k patients) and a business model that sells durable pumps plus single‑use consumables creates durable, repeatable revenue. This recurring demand supports predictable unit economics and higher lifetime customer value, aiding sustainable growth and margin recovery.
High Product Gross MarginsConsistently ~60% gross margins indicate strong product economics and pricing power versus cost of goods. Durable high margins give the company room to invest in sales, R&D and regulatory approvals while still targeting overall profitability as operating leverage improves over the medium term.
Conservative Leverage And Balance SheetLow absolute debt and a low debt/equity ratio imply manageable refinancing risk and financial flexibility. That conservative capital structure supports investment in commercialization and regulatory work without immediate pressure to raise dilutive capital, improving runway for execution.
Bears Say
Persistent Negative ProfitabilityAlthough losses are narrowing, sustained negative operating and net margins mean the company still relies on execution to reach durable profitability. Continued losses can erode equity, limit reinvestment capacity, and necessitate external financing if positive cash flow isn’t maintained.
Uneven Cash GenerationPositive but volatile operating and free cash flow with thin cash conversion indicate limited internal funding for growth. This uneven cash profile raises the likelihood of reliance on credit or equity during investment or seasonal outflows, constraining strategic flexibility.
Operational And Margin Volatility (tariffs, Distributors)Tariff-related cost shocks and distributor-driven, lumpy international orders create recurring margin and revenue timing risk. Such structural volatility complicates forecasting, can delay consumable pull‑through, and may slow the path to consistent adjusted EBITDA and cash generation.
REPRO-MED Systems News
KRMD FAQ
What was REPRO-MED Systems’s price range in the past 12 months?
REPRO-MED Systems lowest stock price was $2.91 and its highest was $6.61 in the past 12 months.
What is REPRO-MED Systems’s market cap?
REPRO-MED Systems’s market cap is $183.73M.
When is REPRO-MED Systems’s upcoming earnings report date?
REPRO-MED Systems’s upcoming earnings report date is Aug 12, 2026 which is in 57 days.
How were REPRO-MED Systems’s earnings last quarter?
REPRO-MED Systems released its earnings results on May 06, 2026. The company reported -$0.02 earnings per share for the quarter, the consensus estimate of -$0.02 by $0.
Is REPRO-MED Systems overvalued?
According to Wall Street analysts REPRO-MED Systems’s price is currently Undervalued.
Does REPRO-MED Systems pay dividends?
REPRO-MED Systems does not currently pay dividends.
What is REPRO-MED Systems’s EPS estimate?
REPRO-MED Systems’s EPS estimate is -0.02.
How many shares outstanding does REPRO-MED Systems have?
REPRO-MED Systems has 45,933,000 shares outstanding.
What happened to REPRO-MED Systems’s price movement after its last earnings report?
REPRO-MED Systems reported an EPS of -$0.02 in its last earnings report, expectations of -$0.02. Following the earnings report the stock price went up 10.723%.
Which hedge fund is a major shareholder of REPRO-MED Systems?
Currently, no hedge funds are holding shares in KRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
REPRO-MED Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.33 (46.27% Upside)
$6.33 (46.27% Upside)
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.99%
12-Months-Change
Fundamentals
Return on Equity
-13.61%
Trailing 12-Months
Asset Growth
5.05%
Trailing 12-Months
Company Description
REPRO-MED Systems
KORU Medical Systems, Inc. is dedicated to the development, manufacturing, and commercialization of mobile medical devices, primarily serving the ambulatory infusion market across both the United States and international territories. The company's primary offerings revolve around mechanical infusion solutions, notably their FREEDOM infusion systems. These comprehensive systems encompass components such as the FREEDOM60 and FreedomEdge syringe drivers, alongside specialized HIgH-Flo subcutaneous safety needle sets and precision flow rate tubing. Beyond their product range, KORU Medical also supplies educational content and training materials to healthcare professionals, patients, and patient advocates. The distribution of their products is managed through a combination of direct sales efforts, partnerships with medical device distributors, and online channels. Established in 1980, the firm's corporate headquarters are situated in Chester, New York.
KRMD Company Deck
KRMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive tone driven by strong top-line growth (22% YoY), substantial PST revenue acceleration (166% YoY), significant international expansion (35% YoY), near-breakeven adjusted EBITDA and minimal cash burn in Q1, alongside meaningful pipeline progress (two programs to Phase III, 510(k) submissions, EU MDR clearance). Key near-term risks include a 130-basis-point gross margin decline (partly tariff-related), an 11% increase in operating expenses, seasonal Q2 cash outflows, and lumpy international distributor-driven revenue timing. On balance, the operational and strategic momentum and reiterated guidance outweigh the noted headwinds.View all KRMD earnings summariesKRMD Stock 12 Month Forecast
Average Price Target
$6.33
▲(46.27% Upside)
Technical Analysis
InfuSystem Holdings
―
Orasure Technologies
―
Utah Medical Products
―
Microbot Medical
―
―
Ownership Overview
16.71% Insiders
9.06% Mutual Funds
24.44% Other Institutional Investors
42.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---